A previously unknown strain of Ebola is spreading through central Africa with little American intervention, following sweeping cuts to US global health programs and the dismantling of key research infrastructure.
The Bundibugyo variant, which lacks both a vaccine and cure, has produced 482 suspected cases and roughly 116 deaths in the Democratic Republic of the Congo since April. Two cases and one death have been reported in Uganda, with potential spread to South Sudan. The World Health Organization declared it a public health emergency of international concern before even convening its standard decision-making committee, signaling rare urgency.
But the American response has been muted. The US Agency for International Development was dismantled in the past year, thousands of health agency staff were laid off, scientific research programs canceled, and communications faltered. The CDC has no director. There is no US surgeon general. The FDA commissioner position stands vacant.
Foreign aid tells the story starkly. US assistance to the DRC dropped from $1.4 billion in 2024 to $431 million in 2025, then to just $21 million so far this year. Uganda saw aid fall from $674 million to $377 million in 2025 and slide into negative territory at $1.2 million for 2026. The US also announced plans to withdraw from the WHO and end $130 million in funding, eliminating 2,371 positions at the organization.
Matthew Kavanagh, director of the Center for Global Health Policy and Politics at Georgetown University, pointed to the timing as catastrophic. "The DRC is one of the most vulnerable health systems in the world, and was the second-biggest recipient of USAID funding," he said. The agency provided "zero notice" before cutting support, he added, disrupting basic health activities across the country.
A critical resource has also gone dark. A world-class Ebola laboratory in Frederick, Maryland, operated by the National Institutes of Health and designed precisely for outbreak scenarios like this one, was shuttered last year with staff laid off abruptly. Research indicating monoclonal antibodies and vaccines might work against this strain, the advanced sequencing work needed to track viral spread, the in-depth sample analysis that could reveal outbreak origins, all stopped with no warning. The lab's website remains closed, showing no signs of revival during the current emergency.
The gap in staffing on the ground mirrors the institutional collapse. The DRC country office now operates with between 25 and 30 personnel. The CDC is sending one additional person. When USAID issued sudden stop-work orders, hundreds of health workers who had been actively hunting for viral spillover in the DRC and Uganda lost their jobs. The broader network suffered too: thousands of community health workers conducting surveillance for HIV, tuberculosis, malaria, maternal and child health, the frontline workers who typically catch outbreaks early, had their positions and funding yanked.
Kristian Andersen, a professor of immunology and microbiology at Scripps Research, stressed the scale of retreat. "It's not just that we're leaving the table, we are completely cutting ourselves out of the conversation," he said. "We are upending the table." He noted that preventing and containing outbreaks costs far less than responding to them after they spread. With the US cutting the prevention option, worse scenarios become inevitable.
The US response has instead pivoted to travel restrictions on noncitizens from affected regions, a move experts dismissed as performance without substance. Kavanagh called it "public health theater" that punishes countries without halting transmission. The Africa CDC urged nations to abandon "fear-driven" travel bans, stating instead that "the fastest path to protecting all countries in the world is to aggressively support outbreak control at the source."
Yet support is withering. When asked about the shuttered NIH lab, a CDC incident manager said he "can't speak" to it during a press conference, deflecting instead to unrelated comments about domestic testing capacity.
Scientists working in the region have seized the initiative. African researchers have already sequenced the virus, demonstrating a fresh spillover event and potentially indicating outbreak origins. But Andersen cautioned against misplaced confidence: "These countries are way more competent than we are in responding to something like Ebola," he said. "But that doesn't mean that we should just completely cut ourselves out of the picture."
Kavanagh framed the stakes as both moral and strategic. "Ebola can be stopped," he said. "If we don't mobilize the dollars and the public health efforts, then we are simply choosing not to stop the outbreak. The question is, will it be? And when?" He warned that the now-borderless outbreak could become a regional crisis, one that might have been detected weeks earlier with intact surveillance networks still in place.
Author James Rodriguez: "You don't dismantle your disease-fighting apparatus mid-pandemic and then claim helplessness when the next crisis crosses a border."
Comments